Relying on data collected by the Zurich Survey of Academics (ZSoA), a unique representative online survey among academics in Germany, Austria, and Switzerland (DACH region), this paper replicates Johann and Mayer’s (Minerva 57(2):175-196, 2019) analysis of researchers’ perceptions of Bio Med Frontiers scientific authorship and expands their scope.
The primary goals of the study at hand are to learn more about (a) country differences in perceptions of scientific authorship, as well as (b) the influence of perceived publication pressure on authorship perceptions.
The results indicate that academics in Switzerland interpret scientific authorship more leniently than their colleagues in Germany and Austria. The Provider findings further indicate that, as perceived pressure to publish increases, researchers are more likely to belong to a group of academics who hold the view that any type of contribution/task justifies co-authorship, including even those contributions/tasks that do not justify co-authorship according to most authorship guidelines.
In summary, the present study suggests that action is required to harmonize regulations for scientific authorship and to improve the research culture.
Rates of publication of FCPS dissertations in international and national peer-review journals among residents at AKUH; A cross sectional review of 15 years.
Size of the science team at university and internal co-publications: science policy implications.
- Scientific collaboration within a science team (unit, group, etc.) has been under scrutiny. Recently, science of team science has emerged to use science for deep understanding of the ways researchers jointly perform science to increase their team’s performance.
- This article analyses internal scientific outputs with respect to the size of university’s science team. The objective is to examine the science policy motive that is, if the team size increases, by encouraging academics to gather in larger teams, then their outputs increase.
- The method of the contrapositive of this conditional statement is adopted. Thus, 120 accredited teams, composed of about 1500 academics in four universities in Morocco, were analyzed using a cross-matrix of members’ co-publications, an intra-collaboration index, Lorenz curve of both internal co-publications and sole-publications, with respect to team’s size.
- Our findings show that internal co-publications and sole ones are higher for small size teams and that the Lorenz distributions of these two indicators are unequal in favor of small size teams. We discuss the implications of our findings for science policy, beyond size, such as the output- instead of input-based perspective to form a team, time requirement to build a collaborative team, inter- and intra-disciplinarity oriented research, team directorship, etc.
Current opinion on the role of vitamin D supplementation in respiratory infections and asthma/COPD exacerbations: A need to establish publication guidelines for overcoming the unpublished data.
Publication Trends of Research on Polypoidal Choroidal Vasculopathy During 2001-2020: A 20-Year Bibliometric Study
Anti-Mouse I-Ab (public; Ia.m8), PE (Clone 28-16-8S) (mouse IgM) |
|||
MBS520492-005mg | MyBiosource | 0.05mg | 300 EUR |
Anti-Mouse I-Ab (public; Ia.m8), PE (Clone 28-16-8S) (mouse IgM) |
|||
MBS520492-5x005mg | MyBiosource | 5x0.05mg | 1100 EUR |
Anti-Mouse I-Ab (public; Ia.m8), FITC (Clone 28-16-8S) (mouse IgM) |
|||
MBS520349-01mg | MyBiosource | 0.1mg | 300 EUR |
Anti-Mouse I-Ab (public; Ia.m8), FITC (Clone 28-16-8S) (mouse IgM) |
|||
MBS520349-5x01mg | MyBiosource | 5x0.1mg | 1105 EUR |
Anti-Mouse I-Ap (public; Ia.m57), PE (Clone 7-16.17) (mouse IgG2a) |
|||
MBS520367-005mg | MyBiosource | 0.05mg | 300 EUR |
Anti-Mouse I-Ap (public; Ia.m57), PE (Clone 7-16.17) (mouse IgG2a) |
|||
MBS520367-5x005mg | MyBiosource | 5x0.05mg | 1100 EUR |
Anti-Mouse I-Ek (public; Ia.m7), PE (Clone 14-4-4S) (mouse IgG2a) |
|||
MBS520372-005mg | MyBiosource | 0.05mg | 300 EUR |
Anti-Mouse I-Ek (public; Ia.m7), PE (Clone 14-4-4S) (mouse IgG2a) |
|||
MBS520372-5x005mg | MyBiosource | 5x0.05mg | 1100 EUR |
Anti-Mouse H-2Ld (public; H-2.m65), PE (Clone 30-5-7S) (mouse IgG2a) |
|||
MBS520335-005mg | MyBiosource | 0.05mg | 300 EUR |
Anti-Mouse H-2Ld (public; H-2.m65), PE (Clone 30-5-7S) (mouse IgG2a) |
|||
MBS520335-5x005mg | MyBiosource | 5x0.05mg | 1100 EUR |
Anti-Mouse I-Ab (public; Ia.m8), Biotin (Clone 28-16-8S) (mouse IgM) |
|||
MBS520348-01mg | MyBiosource | 0.1mg | 300 EUR |
Anti-Mouse I-Ab (public; Ia.m8), Biotin (Clone 28-16-8S) (mouse IgM) |
|||
MBS520348-5x01mg | MyBiosource | 5x0.1mg | 1105 EUR |
Anti-Mouse I-Ap (public; Ia.m57), FITC (Clone 7-16.17) (mouse IgG2a) |
|||
MBS520365-01mg | MyBiosource | 0.1mg | 300 EUR |
Anti-Mouse I-Ap (public; Ia.m57), FITC (Clone 7-16.17) (mouse IgG2a) |
|||
MBS520365-5x01mg | MyBiosource | 5x0.1mg | 1105 EUR |
Anti-Mouse I-Ek (public; Ia.m7), FITC (Clone 14-4-4S) (mouse IgG2a) |
|||
MBS520371-01mg | MyBiosource | 0.1mg | 300 EUR |
Anti-Mouse I-Ek (public; Ia.m7), FITC (Clone 14-4-4S) (mouse IgG2a) |
|||
MBS520371-5x01mg | MyBiosource | 5x0.1mg | 1105 EUR |
Anti-Mouse H-2Ld (public; H-2.m65), FITC (Clone 30-5-7S) (mouse IgG2a) |
|||
MBS520334-01mg | MyBiosource | 0.1mg | 300 EUR |
Anti-Mouse H-2Ld (public; H-2.m65), FITC (Clone 30-5-7S) (mouse IgG2a) |
|||
MBS520334-5x01mg | MyBiosource | 5x0.1mg | 1105 EUR |